Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.15 USD | +5.50% | +4.55% | -20.69% |
Business Summary
Number of employees: 147
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Novel Therapies
100.0
%
| 120 | 100.0 % | 117 | 100.0 % | -2.79% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 120 | 100.0 % | 117 | 100.0 % | -2.79% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Raul Rodriguez
CEO | Chief Executive Officer | 63 | 00-03-31 |
Dean Schorno
DFI | Director of Finance/CFO | 61 | 18-05-28 |
Chief Tech/Sci/R&D Officer | - | 16-08-31 | |
David Santos
PRN | Corporate Officer/Principal | 61 | 20-07-31 |
Julie Patel
HRO | Human Resources Officer | - | 22-03-31 |
Joseph Lasaga
PRN | Corporate Officer/Principal | - | 97-12-31 |
Raymond Furey
LAW | General Counsel | 56 | 22-11-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Gregg Lapointe
CHM | Chairman | 65 | 17-11-01 |
Gary Lyons
BRD | Director/Board Member | 73 | 05-09-30 |
Raul Rodriguez
CEO | Chief Executive Officer | 63 | 00-03-31 |
Walter Moos
BRD | Director/Board Member | 69 | 97-02-28 |
Jane Wasman
BRD | Director/Board Member | 67 | 19-03-25 |
Director/Board Member | 65 | 21-12-15 | |
Alison Hannah
BRD | Director/Board Member | 63 | 21-05-12 |
Brian Kotzin
BRD | Director/Board Member | 74 | 17-08-24 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 175,404,663 | 171,711,369 ( 97.89 %) | 0 | 97.89 % |
Company contact information
Rigel Pharmaceuticals, Inc.
611 Gateway Boulevard Suite 900
94080-1985, South San Francisco
+650 624 1100
http://www.rigel.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-20.69% | 191M | |
-1.65% | 104B | |
+6.75% | 97.47B | |
+5.71% | 22.25B | |
-12.60% | 21.68B | |
-9.70% | 18.2B | |
-39.98% | 17.02B | |
-10.17% | 16.36B | |
+6.12% | 14.39B | |
+35.47% | 12.37B |
- Stock Market
- Equities
- RIGL Stock
- Company Rigel Pharmaceuticals, Inc.